Navigation Links
Covance Board Authorizes $300 Million Stock Buyback
Date:1/25/2012

PRINCETON, N.J., Jan. 25, 2012 /PRNewswire/ -- Covance Inc. (NYSE: CVD) said today that its Board of Directors has authorized the repurchase of up to $300 million of its outstanding common stock. This authorization is in addition to the approximately 800,000 shares remaining under a previously-announced repurchase authorization and currently represents approximately ten percent of the Company's common stock. Any purchases under this buyback would be dependent upon business and market conditions and other factors.  The stock purchases may be made from time to time and may be made through a variety of methods including open market purchases, privately negotiated transactions, block trades, and 10b5-1 plans.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 11,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories,  fluctuations in currency exchange rates, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.

 

 

 


'/>"/>
SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2011 Financial Results Conference Call
2. Covance to Present at Credit Suisse 2011 Healthcare Conference
3. Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey
4. Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China
5. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2011 Financial Results Conference Call
6. Covance to Present at Morgan Stanley Global Healthcare Conference
7. Covance Reports Second Quarter Revenue of $518 Million, GAAP EPS of $0.61, and Pro Forma EPS of $0.66
8. Covance to Present at Bairds 2011 Growth Stock Conference
9. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2011 Financial Results Conference Call
10. Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference
11. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 MedDay, ... disorders, announces that an oral presentation entitled "High doses of ... MS-SPI trial" will be given by Professor Ayman Tourbah ... 2nd Congress of the European Academy of Neurology (EAN) in ... and related disorders 3" will take place on Sunday, 29 ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)... ARANZ Medical  Ltd a specialist ... has been named the Coretex Hi-Tech Emerging Company of the ... Dr Bruce Davey , CEO of ARANZ Medical says, ... good to be recognised for the work we are doing ... in 35 countries around the world from Sub-Saharan Africa through ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... 2016 , ... The University of San Francisco (USF) has named Margaret Wooding ... team of more than 100 full-time faculty and staff, and serve as a member ... August. , Baker comes to USF from the University of Washington in Seattle, where ...
(Date:5/25/2016)... COUNTY, FLA (PRWEB) , ... May 25, 2016 , ... ... latest technology to help turn back the hands of time of female aging. ... aging and childbirth. Women with symptoms such as leakage, laxity, itchiness and pain ...
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State College ... for their work on visual evoked potential and human attention. The article, VEP ... the Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., Pine ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... has announced that it will join America's leading engineers at the American Society ... at the Georgia World Congress Center. , Engineers, speakers and exhibitors from ...
(Date:5/24/2016)... CA (PRWEB) , ... May 24, 2016 , ... According ... found that a group of people randomly assigned to reduce the amount of calories ... a 12 percent drop in body weight enjoyed better sleep, improved quality of life, ...
Breaking Medicine News(10 mins):